Shares in local drugmaker SCI Pharmtech Inc (SCI, 旭富製藥) rose 0.5 percent to NT$60.8 yesterday, weaker than the TAIEX’s 0.85 percent increase, Taiwan Stock Exchange data showed, one day after the company trimmed its capital by NT$380,000 (US$11,988).
The Taoyuan-based company cut its capital by buying back 38,000 common shares from employees and therefore raised its net worth to NT$31.28 per share, from the previous NT$31.27, according to its stock filing.
As of yesterday, SCI shares had fallen 2.09 percent this year, more than the main bourse’s 0.6 percent retreat and the chemical sector’s 1.3 percent slide, the TAIEX said.
Still, Fubon Securities Co (富邦證券) maintained a “buy” rating for the drugmaker, as the company is set to benefit from order reallocations by some clients and its sales of primary drug pipelines remain healthy.
“We maintain our positive earnings outlook for its main drug pipelines,” Fubon research analyst Heather Chang (張雅雯) said in a report.
SCI is an affiliate of Mercuries & Associates Ltd (三商行), whose business interests include Mercuries Life Insurance Co (三商美邦人壽), Mercuries Data Systems Ltd (三商電腦), supermarket chain Simple Mart (美廉社), shoe retailer Family Shoes (鞋全家福), beef noodle chain Sanshang Chiaofu (三商巧福) and other ventures.
The drugmaker is one of the nation’s leading pharmaceutical active-ingredient providers and has expanded into diet, anti-depression and HIV/AIDS medications in recent years to diversify its revenue sources.
SCI is poised to benefit from order reallocations by certain customers, Chang said, adding that primary drug pipelines’ sales look healthy, with a still-intact growth history from gross margin expansions and long-term operations.
The active-pharmaceutical ingredients category used to make hydroxychloroquine, a medicine used to treat or prevent malaria, lupus and rheumatoid arthritis, is on course to outperform estimates, with shipments forecast to surge from 3.3 tonnes last year to 20 tonnes this year, the report said.
At the same time, SCI’s antidepressants unit has struck a new deal with an Indian pharmaceutical firm, with initial shipments to begin soon, the report said.
“We expect antidepressant sales to deliver outstanding growth from mid-year on” after SCI secured a position last year as the secondary supplier for the generic formulation of US drugmaker Eli Lilly and Co’s off-patent fluoxetine at a more competitive price.
SCI posted NT$93 million in revenue last month, down 8.86 percent from the same period last year, the stock filing showed.
As of September last year, pre-tax income totaled NT$266.88 million, or NT$3.15 earnings per share, the filing said.
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
EUROPE ON HOLD: Among a flurry of announcements, Intel said it would postpone new factories in Germany and Poland, but remains committed to its US expansion Intel Corp chief executive officer Pat Gelsinger has landed Amazon.com Inc’s Amazon Web Services (AWS) as a customer for the company’s manufacturing business, potentially bringing work to new plants under construction in the US and boosting his efforts to turn around the embattled chipmaker. Intel and AWS are to coinvest in a custom semiconductor for artificial intelligence computing — what is known as a fabric chip — in a “multiyear, multibillion-dollar framework,” Intel said in a statement on Monday. The work would rely on Intel’s 18A process, an advanced chipmaking technology. Intel shares rose more than 8 percent in late trading after the
GLOBAL ECONOMY: Policymakers have a choice of a small 25 basis-point cut or a bold cut of 50 basis points, which would help the labor market, but might reignite inflation The US Federal Reserve is gearing up to announce its first interest rate cut in more than four years on Wednesday, with policymakers expected to debate how big a move to make less than two months before the US presidential election. Senior officials at the US central bank including Fed Chairman Jerome Powell have in recent weeks indicated that a rate cut is coming this month, as inflation eases toward the bank’s long-term target of two percent, and the labor market continues to cool. The Fed, which has a dual mandate from the US Congress to act independently to ensure